1
|
Maeda A, Araki K, Yamada C, Nakayama S, Shirozu K, Yamaura K. Treatment of trigeminal and glossopharyngeal neuralgia in an adolescent: a case report. JA Clin Rep 2021; 7:61. [PMID: 34365546 PMCID: PMC8349942 DOI: 10.1186/s40981-021-00465-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 07/30/2021] [Accepted: 08/03/2021] [Indexed: 12/03/2022] Open
Abstract
Background Hyperactive dysfunction syndrome (HDS) refers to a constellation of symptoms developing from cranial nerve overactivity caused by neurovascular compression at the root entry or exit zone near the brainstem. Although the combined features of HDS are seen in the elderly, there are no reports of such cases in adolescents, to date. Case presentation A 17-year-old male was diagnosed with right glossopharyngeal neuralgia and treated with microvascular decompression. He experienced new-onset right facial pain later and was diagnosed with right trigeminal neuralgia, which required prompt radiofrequency thermocoagulation of the right mandibular nerve. Follow-up in the third post-treatment year revealed the absence of symptom recurrence. Discussion We report the treatment of a rare case of adolescent-onset combined HDS presenting as trigeminal and glossopharyngeal neuralgia. This report highlights the possibility of combined hyperactive dysfunction syndrome in younger age groups. It is crucial to establish a diagnosis early on for prompt management.
Collapse
Affiliation(s)
- Aiko Maeda
- Department of Anesthesiology and Critical Care Medicine, Kyushu University Hospital, 3-1-1 Maedashi Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan.
| | - Kenzo Araki
- Department of Anesthesiology and Critical Care Medicine, Kyushu University Hospital, 3-1-1 Maedashi Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan
| | - Chiaki Yamada
- Department of Anesthesiology and Critical Care Medicine, Kyushu University Hospital, 3-1-1 Maedashi Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan
| | - Shoko Nakayama
- Operating Rooms, Kyushu University Hospital, Fukuoka, Japan
| | - Kazuhiro Shirozu
- Department of Anesthesiology and Critical Care Medicine, Kyushu University Graduate School of Medicine, Fukuoka, Japan
| | - Ken Yamaura
- Department of Anesthesiology and Critical Care Medicine, Kyushu University Graduate School of Medicine, Fukuoka, Japan
| |
Collapse
|
2
|
Morishita M, Nozaki A, Yamamoto H, Fukumuro N, Mori M, Araki K, Sakamoto F, Nakamura A, Yanagita H. Catalytic activity of Co-nanocrystal-doped tungsten carbide arising from an internal magnetic field. RSC Adv 2021; 11:14063-14070. [PMID: 35423950 PMCID: PMC8697676 DOI: 10.1039/d1ra01181b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 04/01/2021] [Indexed: 11/21/2022] Open
Abstract
Pt is an excellent and widely used hydrogen evolution reaction (HER) catalyst. However, it is a rare and expensive metal, and alternative catalysts are being sought to facilitate the hydrogen economy. As tungsten carbide (WC) has a Pt-like occupied density of states, it is expected to exhibit catalytic activity. However, unlike Pt, excellent catalytic activity has not yet been observed for mono WC. One of the intrinsic differences between WC and Pt is in their magnetic properties; WC is non-magnetic, whereas Pt exhibits high magnetic susceptibility. In this study, the WC lattice was doped with ferromagnetic Co nanocrystals to introduce an ordered-spin atomic configuration. The catalytic activity of the Co-doped WC was ∼30% higher than that of Pt nanoparticles for the HER during the hydrolysis of ammonia borane (NH3BH3), which is currently attracting attention as a hydrogen fuel source. Measurements of the magnetisation, enthalpy of adsorption, and activation energy indicated that the synergistic effect of the WC matrix promoting hydrolytic cleavage of NH3BH3 and the ferromagnetic Co crystals interacting with the nucleus spin of the protons was responsible for the enhanced catalytic activity. This study presents a new catalyst design strategy based on the concept of an internal magnetic field. The WC–Co material presented here is expected to have a wide range of applications as an HER catalyst. The catalytic activity of the Co-doped WC is 30% higher than that of Pt nanoparticles for the hydrogen evolution reaction arising from an internal magnetic field.![]()
Collapse
Affiliation(s)
- M Morishita
- Department of Chemical Engineering and Materials Science, University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - A Nozaki
- Department of Chemical Engineering and Materials Science, University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - H Yamamoto
- Department of Chemical Engineering and Materials Science, University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - N Fukumuro
- Department of Chemical Engineering and Materials Science, University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - M Mori
- Graduate Student of University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - K Araki
- Graduate Student of University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - F Sakamoto
- Graduate Student of University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - A Nakamura
- Graduate Student of University of Hyogo 2167 Shosha Himeji 671-2280 Japan
| | - H Yanagita
- Sanalloy Industry Co., Ltd 290-44 Takahashi, Fukusaki-cho Kanzaki 679-2216 Japan
| |
Collapse
|
3
|
Soares RSB, Souza LRR, Bertolucci MM, Oliveira AD, Demets GJF, Araki K. Critical Parameters for Green Glycoluril
Synthesis. RUSS J GEN CHEM+ 2021. [DOI: 10.1134/s1070363221040253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
4
|
Hasegawa M, Taira M, Kanaya T, Araki K, Watanabe T, Tominaga Y, Kugo Y, Ishida H, Narita A, Ueno T, Ueno T, Sawa Y. Clinical Outcomes for Children with Left Ventricular Noncompaction and Cardiomyopathy. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Shirozu K, Setoguchi H, Araki K, Ando T, Yamaura K. Impact of air-conditioner outlet layout on the upward airflow induced by forced air warming in operating rooms. Am J Infect Control 2021; 49:44-49. [PMID: 32603852 DOI: 10.1016/j.ajic.2020.06.202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 06/23/2020] [Accepted: 06/24/2020] [Indexed: 11/25/2022]
Abstract
BACKGROUND Previously, we found that an upward air current in the head area, induced by forced air warming (FAW), was completely counteracted by downward laminar airflow. However, this study did not include any consideration of the air-conditioner outlet layout (ACOL); hence, its impact remains unclear. METHODS This study was performed in 2 operating rooms (ORs)-ISO classes 5 and 6, which are denoted as OR-5 and OR-6, respectively. Both ORs have distinct ACOLs. The cleanliness, or the number or ratio of shifting artificial particles was evaluated. RESULTS During the first 5 minutes after particles generation, significantly more particles shifted into the surgical field in OR-5 when compared to OR-6 (13,587 [4,341-15,913] and 106 [41-338] particles/cubic foot, P < .0001). Notably, FAW did not increase the number of shifting particles in OR-6. The laminar airflow system fully counteracted the upward airflow caused by FAW in OR-6, where the ACOL covered the operating bed. However, this did not occur in OR-5, where the ACOL did not fully cover the operating bed. CONCLUSIONS Regardless of cleanliness ability of OR, an ACOL that fully covers the operating bed can prevent upward airflow in the head area and reduce the number of artificial particles shifting into the surgical field, which are typically caused by FAW.
Collapse
|
6
|
Araki K, Miyagawa S, Kawamura T, Ishii R, Harada A, Ueno T, Toda K, Kuratani T, Sawa Y. Autologous skeletal myoblast sheet prevents cardiomyocyte ischemia and right heart dysfunction in pressure-overloaded right heart porcine model. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Severe heart failure (HF) with congenital heart disease (CHD) have demonstrated life threatening disorder despite of remarkable progress in medical therapies. Autologous skeletal myoblast sheet transplantation therapy showed clinical efficacy for left ventricular dysfunction by cytokine paracrine effects, which are expected to be sufficiently effective against right ventricular (RV) dysfunction which is often seen in end-stage of CHD patients with severe HF.
Hypothesis
An autologous skeletal myoblast sheet transplantation alleviates RV dysfunction in a pressure-overloaded right heart in a porcine model.
Methods
Five-to-six-month-old Göttingen mini-pigs underwent pulmonary artery banding with vascular occluding system. To create the porcine model of chronic pressure-overloaded right heart, vascular occluding system was gradually inflated, over a month, to make pulmonary stenosis to banding velocity >3.0 m/s measured by echocardiography (UCG), and then fixed for another month. Two months after banding, autologous skeletal myoblast sheet was placed on the epicardium of the RV free wall and followed for 2 months. Groups were as follows: control (C, n=5), sheet implantation (S, n=5). Cardiac function was measured using UCG, cardiac computed tomography (CT), and cardiac catheterization (Cath). Two months after sheet implantation, hearts were dissected for histologic analysis.
Results
Before sheet implantation, RV dysfunction was equal in groups; however, 2 months after sheet implantation, RV dysfunction and myocardial ischemia was significantly ameliorated in group S than group C. On CT, RV ejection fraction exacerbation were well controlled in Group S compared to Group C (S 44.9±2.2 vs C 31.9±2.1% [p=0.0042]). UCG and Cath revealed well maintained systolic and diastolic function in Group S compared to Group C (Tei index: S 0.42±0.06 vs C 0.70±0.07 [p=0.0240], Fraction Area Change: S 45.8±7.8 vs C 19.5±1.3% [p=0.0240], Isovolumic Relaxation Time; S 44.3±9.2 vs C 97.3±9.5 ms [p=0.0304]). On C11-Acetate Positron Emission Tomography, myocardial ischemia was more prominent in Group C compared to Group S (K mono-Rest/Stress: S 3.17±0.69 vs C 2.03±0.65 min-1 [p=0.0421], Myocardial Blood Flow-Rest/Stress: S 3.22±0.39 vs C 2.13±0.92 min-1 [p=0.0421]). In histologic analysis, Group S presented less progressed hypertrophic change in periodic acid-Schiff stain (S 13.5±0.9 vs C 18.0±3.0 μg [p=0.0240]), anti-fibrotic changes in picrosirius red stain (S 3.0±0.3 vs C 4.2±0.2% [p=0.0421]), more angiogenesis in CD31 expression (S 18.3±1.5 vs C 10.7±2.8 / 104 μm2 [p=0.0240]), and less production of reactive oxygen species in fluorescent immunostaining (S 5.9±1.7 vs C 18.4±1.7% [p=0.0304]).
Conclusion
Autologous skeletal myoblast sheet transplantation alleviates cardiomyocyte Ischemia and RV dysfunction in a porcine model of pressure-overloaded right heart.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Araki
- Osaka University, Osaka, Japan
| | | | | | - R Ishii
- Osaka University, Osaka, Japan
| | | | - T Ueno
- Osaka University, Osaka, Japan
| | - K Toda
- Osaka University, Osaka, Japan
| | | | - Y Sawa
- Osaka University, Osaka, Japan
| |
Collapse
|
7
|
Le SH, Tonami K, Umemori S, Nguyen LB, Ngo LQ, Araki K, Nitta H. Relationship between preoperative dental anxiety and short-term inflammatory response following oral surgery. Aust Dent J 2020; 66:13-19. [PMID: 32989884 DOI: 10.1111/adj.12796] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2020] [Indexed: 11/28/2022]
Abstract
BACKGROUND The relationship between dental anxiety and mucosal wound healing, especially the inflammatory response, has not been well studied. This study aimed to examine the relationship between anxiety prior to dental treatment and short-term inflammation following impacted mandibular third molar (IMTM) surgery. METHODS Fifty-nine patients who required IMTM surgery were recruited for this study. Sample demographics (gender, age) and surgical extent (Pederson classification, duration) were collected. Psychological stress towards surgery was assessed by the Dental Fear Survey (DFS). All surgeries were conducted according to an identical surgical protocol and all patients were given the same medical prescription. Correlations between short-term inflammation (swelling and trismus after 2 days) and DFS, demographics and surgical extent were statistically analysed. RESULTS The results showed that patients with a higher DFS score demonstrated more severe swelling (β = 0.36, P = 0.016) and trismus (β = 0.37, P = 0.008) 2 days after surgery. In addition, more severe trismus occurred following more difficult surgery (β = 0.29, P = 0.016) or that with a longer duration (β = 0.21, P = 0.081). Neither gender nor age showed any significant relationship with swelling or trismus. CONCLUSION Short-term inflammatory response following IMTM surgery correlated with the preoperative dental anxiety and this correlation was independent of gender and surgical extent.
Collapse
Affiliation(s)
- S H Le
- Department of Oral Surgery, Faculty of Odonto-Stomatology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - K Tonami
- Oral Diagnosis and General Dentistry, Dental Hospital, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - S Umemori
- Oral Diagnosis and General Dentistry, Dental Hospital, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - Lt-B Nguyen
- Department of Oral Surgery, Faculty of Odonto-Stomatology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Lt-Q Ngo
- Department of Dental Basic Sciences, Faculty of Odonto-Stomatology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - K Araki
- Department of Educational System in Dentistry, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - H Nitta
- Oral Diagnosis and General Dentistry, Dental Hospital, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| |
Collapse
|
8
|
Watanabe A, Yoshizumi T, Harimoto N, Kogure K, Ikegami T, Harada N, Itoh S, Takeishi K, Mano Y, Yoshiya S, Morinaga A, Araki K, Kubo N, Mori M, Shirabe K. Right hepatic venous system variation in living donors: a three-dimensional CT analysis. Br J Surg 2020; 107:1192-1198. [PMID: 32335898 DOI: 10.1002/bjs.11602] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Revised: 02/16/2020] [Accepted: 02/27/2020] [Indexed: 11/09/2022]
Abstract
BACKGROUND The right hepatic venous system consists of the right hepatic vein (RHV) and inferior RHVs (IRHVs). When the right posterior section is used as a graft for liver transplantation, understanding variations and relationships between the RHV and IRHVs is critical for graft venous return and hepatic vein reconstruction. This study aimed to evaluate variations in the hepatic veins and the relationships between them. METHODS The medical records and CT images of patients who underwent hepatectomy as liver donors were assessed retrospectively. The relationship between the veins was evaluated by three-dimensional CT. RESULTS The configuration of the posterior section was classified into one of eight types based on the RHV and IRHVs in 307 patients. Type 1a (103 of 307), type 1b (139 of 307) and type 2a (40 of 307) accounted for 91·9 per cent of the total. The diameter of the RHV extending towards the inferior vena cava had a significant inverse correlation with that of the IRHV (r2 = -0·615, P < 0·001). Type 1a, which had no IRHVs, had the RHV with the largest diameter; conversely, type 2a, which had a large IRHV, had the RHV with the smallest diameter. CONCLUSION The hepatic venous system of the right posterior section was classified into eight types, with an inverse relationship between RHV and IRHV sizes. This information is useful for segment VII resection or when the right liver is used as a transplant graft.
Collapse
Affiliation(s)
- A Watanabe
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.,Department of Hepatobiliary and Pancreatic Surgery, Maebashi Gunma, Japan.,Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi Gunma, Japan
| | - T Yoshizumi
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - N Harimoto
- Department of Hepatobiliary and Pancreatic Surgery, Maebashi Gunma, Japan.,Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi Gunma, Japan
| | - K Kogure
- Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi Gunma, Japan
| | - T Ikegami
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - N Harada
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - S Itoh
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Takeishi
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Mano
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - S Yoshiya
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - A Morinaga
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Araki
- Department of Hepatobiliary and Pancreatic Surgery, Maebashi Gunma, Japan.,Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi Gunma, Japan
| | - N Kubo
- Department of Hepatobiliary and Pancreatic Surgery, Maebashi Gunma, Japan.,Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi Gunma, Japan
| | - M Mori
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Shirabe
- Department of Hepatobiliary and Pancreatic Surgery, Maebashi Gunma, Japan.,Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi Gunma, Japan
| |
Collapse
|
9
|
Araki K, Suzawa K, Miyauchi S, Miura A, Namba K, Otani S, Yamamoto H, Okazaki M, Sugimoto S, Yamane M, Toyooka S. EP1.01-18 Clinical Features of Locally Advanced Lung Cancer Patients with Radiation Pneumonitis After Induction Chemoradiotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
10
|
Seto J, Wada T, Suzuki Y, Ikeda T, Araki K, Umetsu Y, Ishikawa H, Mizuta K, Ahiko T. A case of laboratory cross-contamination of Mycobacterium tuberculosis identified using comparative genomics. Int J Tuberc Lung Dis 2019; 22:1239-1242. [PMID: 30236195 DOI: 10.5588/ijtld.18.0237] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Two false-positive tuberculosis (TB) cases in Yamagata Prefecture, Japan, 2016. OBJECTIVE To report the effectiveness of comparative genomics of Mycobacterium tuberculosis for identification of cross-contamination cases. DESIGN Case report of laboratory cross-contamination. RESULTS Beginning with detection of an identical genotype in two M. tuberculosis strains using variable number of tandem repeat typing, we suspected M. tuberculosis cross-contamination of specimens collected in a mycobacteriology laboratory based on epidemiological investigations. This suspicion was confirmed using comparative genomics of the two M. tuberculosis strains and a strain from an epidemiologically unrelated specimen from the same batch as the two strains in the mycobacteriology laboratory. All strains had an identical genomic sequence with no single nucleotide variants. CONCLUSION Comparative genomics, which offers the highest discrimination power, is a potent tool for identifying laboratory cross-contamination using epidemiological investigations.
Collapse
Affiliation(s)
- J Seto
- Yamagata Prefectural Institute of Public Health, Yamagata
| | - T Wada
- Nagasaki University, Nagasaki
| | - Y Suzuki
- Yamagata Prefectural Institute of Public Health, Yamagata
| | - T Ikeda
- Yamagata Prefectural Institute of Public Health, Yamagata
| | - K Araki
- Murayama Public Health Center, Yamagata
| | - Y Umetsu
- Okitama Public Health Center, Yamagata
| | - H Ishikawa
- Shonai Public Health Center, Yamagata, Japan
| | - K Mizuta
- Yamagata Prefectural Institute of Public Health, Yamagata
| | - T Ahiko
- Yamagata Prefectural Institute of Public Health, Yamagata, Murayama Public Health Center, Yamagata
| |
Collapse
|
11
|
Miyazaki T, Zhao Z, Ichihara Y, Yoshino D, Imamura T, Sawada K, Hayano S, Kamioka H, Mori S, Hirata H, Araki K, Kawauchi K, Shigemoto K, Tanaka S, Bonewald LF, Honda H, Shinohara M, Nagao M, Ogata T, Harada I, Sawada Y. Mechanical regulation of bone homeostasis through p130Cas-mediated alleviation of NF-κB activity. Sci Adv 2019; 5:eaau7802. [PMID: 31579816 PMCID: PMC6760935 DOI: 10.1126/sciadv.aau7802] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 09/03/2019] [Indexed: 05/07/2023]
Abstract
Mechanical loading plays an important role in bone homeostasis. However, molecular mechanisms behind the mechanical regulation of bone homeostasis are poorly understood. We previously reported p130Cas (Cas) as a key molecule in cellular mechanosensing at focal adhesions. Here, we demonstrate that Cas is distributed in the nucleus and supports mechanical loading-mediated bone homeostasis by alleviating NF-κB activity, which would otherwise prompt inflammatory processes. Mechanical unloading modulates Cas distribution and NF-κB activity in osteocytes, the mechanosensory cells in bones. Cas deficiency in osteocytes increases osteoclastic bone resorption associated with NF-κB-mediated RANKL expression, leading to osteopenia. Upon shear stress application on cultured osteocytes, Cas translocates into the nucleus and down-regulates NF-κB activity. Collectively, fluid shear stress-dependent Cas-mediated alleviation of NF-κB activity supports bone homeostasis. Given the ubiquitous expression of Cas and NF-κB together with systemic distribution of interstitial fluid, the Cas-NF-κB interplay may also underpin regulatory mechanisms in other tissues and organs.
Collapse
Affiliation(s)
- T. Miyazaki
- Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo 173-0015, Japan
- Department of Orthopaedic Surgery, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo 173-0015, Japan
- Corresponding author. (T.M.); (Y.S.)
| | - Z. Zhao
- Mechanobiology Institute, National University of Singapore, Level 10, T-Lab, 5A Engineering Drive 1, Singapore 117411, Singapore
- Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543, Singapore
| | - Y. Ichihara
- Department of Rehabilitation for Motor Functions, Research Institute, National Rehabilitation Center for Persons with Disabilities, Tokorozawa, Saitama 359-8555, Japan
- Division of Pharmacology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - D. Yoshino
- Mechanobiology Institute, National University of Singapore, Level 10, T-Lab, 5A Engineering Drive 1, Singapore 117411, Singapore
- Creative Interdisciplinary Research Division, Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan
| | - T. Imamura
- Division of Pharmacology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - K. Sawada
- Mechanobiology Institute, National University of Singapore, Level 10, T-Lab, 5A Engineering Drive 1, Singapore 117411, Singapore
- Laboratory for Mechanical Medicine, Nadogaya Research Institute, Nadogaya Hospital, Kashiwa, Chiba 277-0032, Japan
| | - S. Hayano
- Department of Orthodontics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Okayama 700-8525, Japan
| | - H. Kamioka
- Department of Orthodontics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Okayama 700-8525, Japan
| | - S. Mori
- Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo 173-0015, Japan
| | - H. Hirata
- Mechanobiology Institute, National University of Singapore, Level 10, T-Lab, 5A Engineering Drive 1, Singapore 117411, Singapore
| | - K. Araki
- Mechanobiology Institute, National University of Singapore, Level 10, T-Lab, 5A Engineering Drive 1, Singapore 117411, Singapore
| | - K. Kawauchi
- Mechanobiology Institute, National University of Singapore, Level 10, T-Lab, 5A Engineering Drive 1, Singapore 117411, Singapore
| | - K. Shigemoto
- Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo 173-0015, Japan
| | - S. Tanaka
- Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
| | - L. F. Bonewald
- Indiana Center for Musculoskeletal Health, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
| | - H. Honda
- Field of Human Disease Models, Institute of Laboratory Animals, Tokyo Women’s Medical University, Tokyo 162-8666, Japan
| | - M. Shinohara
- Department of Rehabilitation for Motor Functions, Research Institute, National Rehabilitation Center for Persons with Disabilities, Tokorozawa, Saitama 359-8555, Japan
- Precursory Research for Embryonic Science and Technology (PRESTO), Japan Science and Technology Agency (JST), Saitama 332-0012, Japan
| | - M. Nagao
- Department of Rehabilitation for Motor Functions, Research Institute, National Rehabilitation Center for Persons with Disabilities, Tokorozawa, Saitama 359-8555, Japan
| | - T. Ogata
- Department of Rehabilitation for Motor Functions, Research Institute, National Rehabilitation Center for Persons with Disabilities, Tokorozawa, Saitama 359-8555, Japan
| | - I. Harada
- Laboratory for Mechanical Medicine, Nadogaya Research Institute, Nadogaya Hospital, Kashiwa, Chiba 277-0032, Japan
| | - Y. Sawada
- Mechanobiology Institute, National University of Singapore, Level 10, T-Lab, 5A Engineering Drive 1, Singapore 117411, Singapore
- Department of Rehabilitation for Motor Functions, Research Institute, National Rehabilitation Center for Persons with Disabilities, Tokorozawa, Saitama 359-8555, Japan
- Laboratory for Mechanical Medicine, Nadogaya Research Institute, Nadogaya Hospital, Kashiwa, Chiba 277-0032, Japan
- Department of Clinical Research, National Rehabilitation Center for Persons with Disabilities, Tokorozawa, Saitama 359-8555, Japan
- Corresponding author. (T.M.); (Y.S.)
| |
Collapse
|
12
|
Araki K, Fujisawa T, Sakamaki K, Kikawa Y, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N. Abstract P4-13-09: Sequential second line endocrine therapy is still an effective strategy for postmenopausal ER+ and HER2- advanced breast cancer with low sensitivity to initial endocrine therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:It is unclear how to define responsiveness to endocrine therapy (ET) during the clinical course of advanced breast cancer (ABC), especially in evaluation of the effect of sequential ET. Objective:The goal of the study was to evaluate the efficacy of second line treatment of physician's choice (2nd-line TPC) for estrogen receptor-positive (ER+) and HER2-negative postmenopausal ABC with very low or low sensitivity to initial ET. Methods:A multicenter prospective observational cohort study was performed for 2nd-line TPCs. ABC with low sensitivity to initial ET was defined as recurrence within 5 years (yrs) during adjuvant ET or progression within 9 months (mo.) of initial ET. Similarly, ABC with very low sensitivity to initial ET was defined as recurrence within 2 yrs during adjuvant ET or progression within 3 mo. of initial ET. The expected clinical benefit rate (CBR: defined as patients who achieved CR, PR or SD for 24 weeks) was 50%. The null hypothesis of a CBR of 30% was tested with a one-sided α of 5%. 90% confidence intervals (CIs) were calculated for hypothesis tests. Results: A total of 56 patients (pts) were enrolled, but 7 were ineligible and one discontinued before starting the protocol treatment. The median age was 66 yrs (range: 41-88) and the median BMI was 23.4 kg/m2 (16.4-31.9). All pts were ER+ and 80% were PgR+. Most of pts had a baseline PS of 0 or 1, 90% had invasive ductal carcinoma, and 10% had invasive lobular carcinoma. Postoperative recurrence was detected in 84% and these pts had a median duration of adjuvant ET of 30.5 mo. (5.3-58.9). De novo stage IV ABC was present in 16%, with a median duration of first-line ET of 5 mo. (2.3-10.8). Adjuvant chemotherapy including anthracycline- and/or a taxane-containing regimen was administered in 58% (29/49). As adjuvant ET before initial recurrence, 34 pts received non-steroidal aromatase inhibitors (AIs) (88.0%), 1 received a steroidal AI (2.3%), and 3 received a selective estrogen receptor modulator (SERM). As first line ET in de novo stage IV, 7 pts (14%) were treated with AIs or a SERM (1 case). 2nd-line TPCs were also used, with 40 pts receiving fulvestrant (82%), 5 receiving SERMs (10%), 3 receiving a mTOR inhibitor plus a steroidal AI (6%), and one patient receiving an AI alone. The overall CBR was 44.9% (90% CI: 34.6-57.6, p=0.009), and CBR was similar across following subgroups (PgR+: n=39, 51.3%, 90% CI: 39.6-65.2, p=0.0016; very low sensitivity group: n=17, 58.8%, 90% CI: 42.0-78.8, p=0.003; non-visceral metastases: n=25, 40%, 90% CI; 34.1-65.9, p=0.0175). However, there were not statistically significant CBR in PgR- (n=10, 20.0%, 90% CI; 8.73-50.7, p=0.617), fulvestrant subgroup (n=40, 40.0 %, 90% CI; 29.2-54.2, p=0.063), low sensitive group (n=32, 37.5%, 90% CI; 26.0-53.6, p=0.1326), and visceral metastases (n=24, 48%, 90%CI; 28.2-60.3 p=0.072). The median PFS was 7.1 mo. (95% CI: 5.6-10.6). Conclusion:This study shows that 2nd line ETs was effective and might be a valid option in the sequence of treatments for postmenopausal women with ABC with low sensitivity to initial ET. It was suggested that PgR and visceral metastasis were significant predictive factors for CBR.
Citation Format: Araki K, Fujisawa T, Sakamaki K, Kikawa Y, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N. Sequential second line endocrine therapy is still an effective strategy for postmenopausal ER+ and HER2- advanced breast cancer with low sensitivity to initial endocrine therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-09.
Collapse
Affiliation(s)
- K Araki
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Fujisawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - K Sakamaki
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - Y Kikawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Iwamoto
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Sangai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Shien
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - S Takao
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - R Nishimura
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - M Takahashi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Aihara
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - H Mukai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - N Taira
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| |
Collapse
|
13
|
Masuda N, Yamashita T, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Abstract OT2-07-05: A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel + Trastuzumab (H) + Pertuzumab (P) provided progression-free survival (PFS) and overall survival (OS) benefits in HER2-positive advanced or metastatic breast cancer (AMBC) in the CLEOPATRA study as a first-line therapy. However, long-term administration of docetaxel at a dose of 75 mg/m2 every 3 weeks in AMBC patients (pts) is difficult due to the toxicities. Eribulin mesylate (E) is a well-tolerated microtubule inhibitor, and we have reported the efficacy and safety of EHP regimen as first- and second-line therapy for AMBC in a multicenter, phase II study (JBCRG-M03/UMIN000012232). In this M06 study, we address the clinical question as to which is the better chemotherapy partner for HP as first line regimen, in terms of efficacy, toxicity and QOL.
Methods: JBCRG-M06 is a multicenter open-label randomized phase III study for HER2-positive AMBC pts who have received no prior chemotherapy except for the HER2- Antibody-Drug Conjugate (ADC). Pts will be randomized 1:1 to E (1.4mg/m2 on day 1 and 8) + H (8 mg/kg loading dose followed by 6 mg/kg) +P (840 mg loading dose followed by 420 mg) q3wks or standard taxanes (docetaxel 75mg/m2 on day1 or paclitaxel 80mg/m2 on day 1, 8 and 15) + HP q3wks. Stratification factors for randomization are; presence of visceral metastases, number of prior taxanes on perioperative adjuvant treatment, and treatment with prior anti-HER2-ADC. Primary endpoint is PFS and secondary endpoints include overall response rate, duration of response, OS, patient-reported outcomes (PRO) relating to QOL and peripheral neuropathy, new-metastases free survival, and safety. Translational research to search for biomarker for individual precision therapy will be performed. Main eligibility criteria are as follows: pts with HER2-positive AMBC, female aged 20-70 years old, ECOG PS of 0-1, LVEF ≥ 50% at baseline and adequate organ function. Pts who had progressive MBC within 6 months after the end of primary adjuvant systemic chemotherapy are excluded. The sample size was calculated by type1 error (2-sided) of 0.05 and 80% power to estimate the noninferiority margin 1.33 with an expected median PFS of 14.2 months. The target number of pts is 480 recruited over the duration of 3-years. The first patient in was achieved on August 2017. (ClinicalTrials.gov Identifier:NCT03264547).
Citation Format: Masuda N, Yamashita T, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-07-05.
Collapse
Affiliation(s)
- N Masuda
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Yamashita
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Saji
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Araki
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Ito
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Takano
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - M Takahashi
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - J Tsurutani
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Koizumi
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - M Kitada
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Kojima
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Sagara
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - H Tada
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Iwasa
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Kadoya
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Iwatani
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - H Hasegawa
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Morita
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Ohno
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| |
Collapse
|
14
|
Seto J, Otani Y, Wada T, Suzuki Y, Ikeda T, Araki K, Mizuta K, Ahiko T. Nosocomial Mycobacterium tuberculosis transmission by brief casual contact identified using comparative genomics. J Hosp Infect 2019; 102:116-119. [PMID: 30629999 DOI: 10.1016/j.jhin.2019.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 01/02/2019] [Indexed: 10/27/2022]
Abstract
This paper reports a case of nosocomial transmission of Mycobacterium tuberculosis by brief casual contact. Routine variable number tandem repeat typing in Yamagata Prefecture, Japan found that M. tuberculosis clinical isolates from two patients showed indistinguishable genotypes. The patients had an epidemiological relationship of sharing a waiting room in a hospital on the same day. As comparative genomics detected only two single nucleotide variants between the isolates, it was concluded that recent tuberculosis transmission occurred in the waiting room. These results indicate that the physical separation of infectious tuberculosis patients is an essential control measure for preventing unpredictable nosocomial transmission by casual contact.
Collapse
Affiliation(s)
- J Seto
- Yamagata Prefectural Institute of Public Health, Yamagata, Japan.
| | - Y Otani
- Shonai Public Health Centre, Yamagata, Japan
| | - T Wada
- Nagasaki University, Nagasaki, Japan
| | - Y Suzuki
- Yamagata Prefectural Institute of Public Health, Yamagata, Japan
| | - T Ikeda
- Yamagata Prefectural Institute of Public Health, Yamagata, Japan
| | - K Araki
- Murayama Public Health Centre, Yamagata, Japan
| | - K Mizuta
- Yamagata Prefectural Institute of Public Health, Yamagata, Japan
| | - T Ahiko
- Yamagata Prefectural Institute of Public Health, Yamagata, Japan; Murayama Public Health Centre, Yamagata, Japan
| |
Collapse
|
15
|
Rodrigues-Jesus MJ, Fotoran WL, Cardoso RM, Araki K, Wunderlich G, Ferreira LCS. Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic Escherichia coli strains (EHEC). Braz J Microbiol 2019; 50:67-77. [PMID: 30637647 PMCID: PMC6863297 DOI: 10.1007/s42770-018-0035-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Accepted: 09/24/2018] [Indexed: 01/08/2023] Open
Abstract
Microlipid vesicles (MLV) have a broad spectrum of applications for the delivery of molecules, ranging from chemical compounds to proteins, in both in vitro and in vivo conditions. In the present study, we developed a new set of nanosize multilayer lipid vesicles (NMVs) containing a unique combination of lipids. The NMVs enable the adsorption of histidine-tagged proteins at the vesicle surface and were demonstrated to be suitable for the in vivo delivery of antigens. The NMVs contained a combination of neutral (DOPC) and anionic (DPPG) lipids in the inner membrane and an external layer composed of DOPC, cholesterol, and a nickel-containing lipid (DGS-NTA [Ni]). NMVs combined with a recombinant form of the B subunit of the Shiga toxin (rStx2B) produced by certain enterohemorragic Escherichia coli (EHEC) strains enhanced the immunogenicity of the antigen after parenteral administration to mice. Mice immunized with rStx2B-loaded NMVs elicited serum antibodies capable of neutralizing the toxic activities of the native toxin; this result was demonstrated both in vitro and in vivo. Taken together, these results demonstrated that the proposed NMVs represent an alternative for the delivery of antigens, including recombinant proteins, generated in different expression systems.
Collapse
Affiliation(s)
- M J Rodrigues-Jesus
- Vaccine Development Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, Cidade Universitária, São Paulo, SP, 05508-900, Brazil
| | - W L Fotoran
- Unit for Drug Development and Plasmodium Molecular Biology, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
| | - R M Cardoso
- Supramolecular Chemistry and Nanotechnology Laboratory, Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil
| | - K Araki
- Supramolecular Chemistry and Nanotechnology Laboratory, Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil
| | - G Wunderlich
- Unit for Drug Development and Plasmodium Molecular Biology, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
| | - Luís C S Ferreira
- Vaccine Development Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, Cidade Universitária, São Paulo, SP, 05508-900, Brazil.
| |
Collapse
|
16
|
Takahashi Y, Soh J, Miyauchi S, Araki K, Miura A, Kurihara E, Ogoshi Y, Shien K, Yamamoto H, Sugimoto S, Yamane M, Kiura K, Kanazawa S, Toyooka S. P1.17-17 The Impact of Induction Chemoradiotherapy Followed by Surgery for N1 Involved Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Soh J, Miyauchi S, Araki K, Miura A, Takahashi Y, Kurihara E, Ogoshi Y, Shien K, Yamamoto H, Sugimoto S, Yamane M, Kiura K, Kanazawa S, Toyooka S. P1.17-15 Perioperative Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Aguiar JD, Bezerra CP, Fernandes MS, SuRredini IB, Toma SH, Araki K, Dutra-Correa M, Medeiros IS. Resistência de União à Dentina de um Sistema Adesivo com Diferentes Concentrações de Nanopartículas de Prata. J Health Scie 2018. [DOI: 10.17921/2447-8938.2017v19n5p124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
O objetivo do estudo foi incorporar diferentes concentrações de nanopartículas de prata (NAg) em sistema adesivo e avaliar sua influência na resistência de união à dentina. Quarenta e oito terceiros molares humanos hígidos (CEP 204.601) foram distribuídos aleatoriamente em 12 grupos (n4): controle Scotchbond Multi-Purpose (SBMP), adição de 50, 100, 150, 200 e 250 ppm de NAg no primer do SBMP, avaliados após 24h e 6 meses. Os dentes foram preparados, restaurados, seccionados em palitos (0,7 ± 0,2 mm2) e ensaiados à microtração (μTBS). Os grupos NAg 200ppm e NAg 250ppm apresentaram os maiores valores de μTBS, semelhantes ao SBMP considerando os tempos de avaliação (24h ou 6m). Os grupos NAg 50ppm (6m), NAg 100ppm (24h) e NAg 150ppm (24h e 6m) apresentaram menores valores de µTBS, semelhantes entre si e estatisticamente inferiores ao SBMP (49,4MPa). As demais condições experimentais apresentaram valores semelhantes ao SBMP (24h e 6m). Concluiu-se que a incorporação de concentrações de 200 e 250 ppm de NAg não alterou a resistência de união do sistema adesivo à dentina.Palavras-chave: Adesivos Dentinários. Prata. Resistência à Tração.
Collapse
|
19
|
Araki K, Ito Y, Fukada I, Kobayashi K, Ohno S, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Miyoshi Y. Abstract P2-09-31: Predictive impact of absolute lymphocyte counts for progression-free survival in HER2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor-infiltrating lymphocytes might be a one of predictive outcome of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) patients (pts) who treated with trastuzumab and pertuzumab (TP) plus docetaxel. Although peripheral blood-based parameter (PBBP) is reported as a prognostic indicator of patients with early breast cancers, utility of PBBP has not been studied in HER2-positive ABC.
Objective:The aim of our study was to determine whether PBBP is significant for predictive efficacy in HER2-positive ABC treated with TP combined with eribulin (ERI) or nab-paclitaxel (Nab-PTX).
Methods: The 51 patients' data from two single arm phase II trials was included in this retrospective-prospective study; ERI + TP (n=30) or Nab-PTX + TP (n=21) registered with UMIN000012375 or UMIN000006838, respectively. We assessed the PBBP in prospectively collected data and investigated their association with progression-free survival (PFS). In consideration of PBBP, we evaluated absolute lymphocyte count (ALC), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR). The cutoff values of ALC, NLR, and PLR were set at 1000 cells/μL, 2, and 250, respectively.
Results:Median age at baseline was 58 years (range: 31-77). Median number of previous chemotherapy was 3 (range: 1-10). Pts had multiple metastases, 53% with LNs, 35% with bone, 25% with lung, 20% with liver, and 6% with brain. The objective response rate (CR+PR) and clinical benefit rate (CR+PR+ more than 6 month SD) were 37% (n=19) and 59% (n=30), respectively. The median PFS of all pts was 301 days (range: 21-1281). The PFS of pts with ALC-High was significantly better than those of ALC-low (hazard ratio (HR): 2.74, 95% confidence interval (CI): 1.28 to 5.86; p= .0097). Furthermore, improved PFS was obtained in pts with ALC greater than 1500 cells/μL compared with less than 1000 cells/uL (HR: 4.05, 95% CI: 1.60 to 11.6; p= .0029). Significant associations seem to exist irrespective of number of previous chemotherapy. Since we combined different studies for evaluating PBBP, ERI and Nab-PTX were calculated separately. Marginally significant associations between ALC and PFS were obtained both in ERI (HR: 2.18, 95% CI: 0.87 to 5.60; p=.0973) and Nab-PTX (HR: 3.26, 95% CI: 0.80 to 12.4; p=.0939). The PFS of NLR-low pts was significantly better than those of NLR-high (HR: 2.29, 95% CI: 1.01 to 5.90; p= .0477), but this statistical difference was inferior to those of ALC. There was no significant association between PLR and PFS.
Conclusions: Pre-treatment ALC-High was significantly correlated with favorable PFS of pts treated with TP irrespective of combination chemotherapy in HER2-positve ABC. Prolonged PFS of TP combination therapy might be obtained mediating through host systemic onco-immunity. These data obtained here suggest that a usefulness of ALC for selecting pts who might have clinical benefit from TP combination therapy for heavily treated HER2-positve ABC.
Citation Format: Araki K, Ito Y, Fukada I, Kobayashi K, Ohno S, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Miyoshi Y. Predictive impact of absolute lymphocyte counts for progression-free survival in HER2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-31.
Collapse
Affiliation(s)
- K Araki
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Ito
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - I Fukada
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - K Kobayashi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - S Ohno
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Miyagawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - M Imamura
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - A Kira
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Takatsuka
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - C Egawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - H Suwa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Miyoshi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| |
Collapse
|
20
|
Aguiar J, Suffredini I, Toma S, Araki K, Dutra-Correa M, Medeiros I. Etch-and-rinse adhesive containing silver nanoparticles: Preliminary study of antibacterial effects. Dent Mater 2018. [DOI: 10.1016/j.dental.2018.08.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
sr, Araki K, Ghani HA, Al-Zoubi IA, Sghaireen MG, Gudipaneni RK, Alam MK. A Cone Beam Computed Tomography Study of the Prevalence of Pulp Stones in a Saudi Arabian Adolescent Population. Pesqui bras odontopediatria clín integr 2018. [DOI: 10.4034/pboci.2018.181.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Yurugi Y, Fujiwara W, Kidokoro Y, Hosoya K, Ohno T, Sakabe T, Kubouchi Y, Wakahara M, Takagi Y, Haruki T, Nosaka K, Miwa K, Araki K, Taniguchi Y, Shiomi T, Nakamura H, Umekita Y. P1.02-060 Podoplanin Expression in Cancer-Associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
23
|
Nakamura K, Alam M, Jiang Y, Mitarai O, Kurihara K, Kawamata Y, Sueoka M, Takechi M, Hasegawa M, Tokunaga K, Araki K, Zushi H, Hanada K, Fujisawa A, Idei H, Nagashima Y, Kawasaki S, Nakashima H, Higashijima A, Nagata T, Fukuyama A. Plasma equilibrium based on RF-driven current profile without assuming nested magnetic surfaces on QUEST. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.05.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Kubouchi Y, Fujiwara W, Kidokoro Y, Ohno T, Yurugi Y, Wakahara M, Takagi Y, Miwa K, Araki K, Taniguchi Y, Nakamura H, Umekita Y. P1.02-061 Podoplanin Expression in Cancer-Associated Fibroblasts Predicts Unfavorable Prognosis in Patients with Stage IA Adenocarcinoma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Doki T, Yamashita S, Wei F, Zhang X, Zhang Z, Tawara N, Hino H, Uyama E, Araki K, Ando Y. Polyalanine expansion in PABPN1 causes mitochondrial dysfunction. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Araki K, Nakamura T, Horie K, Kobayashi Y, Kawakami O, Hamada K, Ando T, Katsuno M. Clinical features of epilepsy patients on hemodialysis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
27
|
Araki K, Naoto Y, Ikenaka K, Hayakawa H, Baba K, Nagai Y, Mochizuki H. Fine structure analysis of alpha-synuclein aggregates in the patient’s brain with synchrotron radiation. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Ikenaka K, Aguirre C, Araki K, So M, Kakuda K, Nagano S, Hideki M. Structural variations in αSyn fibrils of Parkinson’s disease and related disorders. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Wang Z, Hanada K, Yoshida N, Shimoji T, Miyamoto M, Oya Y, Zushi H, Idei H, Nakamura K, Fujisawa A, Nagashima Y, Hasegawa M, Kawasaki S, Higashijima A, Nakashima H, Nagata T, Kawaguchi A, Fujiwara T, Araki K, Mitarai O, Fukuyama A, Takase Y, Matsumoto K. Measurement of thickness of film deposited on the plasma-facing wall in the QUEST tokamak by colorimetry. Rev Sci Instrum 2017; 88:093502. [PMID: 28964174 DOI: 10.1063/1.5000739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Accepted: 08/17/2017] [Indexed: 06/07/2023]
Abstract
After several experimental campaigns in the Kyushu University Experiment with Steady-state Spherical Tokamak (QUEST), the originally stainless steel plasma-facing wall (PFW) becomes completely covered with a deposited film composed of mixture materials, such as iron, chromium, carbon, and tungsten. In this work, an innovative colorimetry-based method was developed to measure the thickness of the deposited film on the actual QUEST wall. Because the optical constants of the deposited film on the PFW were position-dependent and the extinction coefficient k1 was about 1.0-2.0, which made the probing light not penetrate through some thick deposited films, the colorimetry method developed can only provide a rough value range of thickness of the metal-containing film deposited on the actual PFW in QUEST. However, the use of colorimetry is of great benefit to large-area inspections and to radioactive materials in future fusion devices that will be strictly prohibited from being taken out of the limited area.
Collapse
Affiliation(s)
- Z Wang
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - K Hanada
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - N Yoshida
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - T Shimoji
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - M Miyamoto
- Department of Material Science, Shimane University, Matsue, Shimane 690-8504, Japan
| | - Y Oya
- Faculty of Science, Shizuoka University, Ohya, Shizuoaka 422-8529, Japan
| | - H Zushi
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - H Idei
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - K Nakamura
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - A Fujisawa
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - Y Nagashima
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - M Hasegawa
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - S Kawasaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - A Higashijima
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - H Nakashima
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - T Nagata
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - A Kawaguchi
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - T Fujiwara
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - K Araki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - O Mitarai
- Institute of Industrial Science and Technology Research, Tokai University, Kumamoto 862-8652, Japan
| | - A Fukuyama
- Department of Nuclear Engineering, Kyoto University, Kyoto 606-8501, Japan
| | - Y Takase
- Graduate School of Frontier Sciences, University of Tokyo, Kashiwa, Chiba 277-8561, Japan
| | - K Matsumoto
- Honda R&D Co., Ltd. Automobile R&D Center, Haga, Tochigi 321-3393, Japan
| |
Collapse
|
30
|
Toya C, Muramoto H, Iwai S, Higuchi K, Tsunamoto H, Matsumoto S, Ozawa T, Araki K, Ohnishi T, Kobayashi I, Ohnishi Y, Umezawa S, Niwa A, Hirao K. 1680The assessment of left atrial appendage flow by computed tomography using serial snapshots method. Europace 2017. [DOI: 10.1093/ehjci/eux160.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Iwai S, Higuchi K, Toya C, Muramoto H, Tsunamoto H, Matsumoto S, Ozawa T, Araki K, Onishi T, Kobayashi I, Onishi Y, Umezawa S, Niwa A, Hirao K. P1401Distributions and correlation of left atrial low voltage zone detected by high density multi-electrode catheter during atrial fibrillation and sinus rhythm. Europace 2017. [DOI: 10.1093/ehjci/eux158.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Iwai S, Higuchi K, Toya C, Muramoto H, Tsunamoto H, Matsumoto S, Ozawa T, Araki K, Onishi T, Kobayashi I, Onishi Y, Umezawa S, Niwa A, Hirao K. P934The electroanatomical characteristics of the patients who need epicardial coronary sinus approach for complete conduction block along mitral isthmus. Europace 2017. [DOI: 10.1093/ehjci/eux151.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Toya C, Higuchi K, Iwai S, Hirotaka M, Tsunamoto H, Matsumoto S, Ozawa T, Araki K, Ohnishi T, Kobayashi I, Ohnishi Y, Umezawa S, Niwa A, Yokoyama Y, Hirao K. P341Comparison of locations between continuous wavelet transform analysis and complex fractionated atrial electrogram in patients with persistent atrial fibrillation. Europace 2017. [DOI: 10.1093/ehjci/eux141.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Araki K, Fukada I, Kobayashi K, Takahashi S, Ito Y. Abstract P5-15-11: Eribulin should be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2 positive advance breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-15-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pertuzumab (P) improves clinical outcome when combined with docetaxel and trastuzumab (T). The efficacy of continuing multiple anti-HER2 therapy including P and/or T after initial progression is unclear. Eribulin mesylate (ERI) is able to overcome taxane (TAX) resistance advanced breast cancer (ABC). The objective of this study is to investigate the efficacy and safety of ERI plus P and T for both TAX and T pretreated HER2-positive ABC. Methods: This is a single institute, open-label, single-arm, Phase II study with pharmacokinetics (PK) of ERI (UMIN000012375). The initial dose of P is 840 mg, followed by 420 mg q3w; the initial dose of T 8 mg/kg, followed by 6 mg/kg q3w; ERI is administered at 1.4 mg on Days 1 and 8 of each cycle, q3w. Dose reductions of ERI (to 1.1 and 0.7 mg/m2) were permitted to manage any toxicity (more than grade 3). Patients (Pts) must have previous treatment with both TAX and T. The primary endpoint is assessed overall response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), safety, and PK of ERI. Left ventricular ejection function (LVEF) was evaluated before and end of this study. Results: Thirty Pts were enrolled. Median age at baseline was 57 years. Half of Pts had endocrine positive. All Pts were treated with TAX and T. Twenty-one Pts were treated with anthracycline-based treatment (70%). Median number of previous chemotherapy was 4 (2-5). Pts had multiple metastases, 40% with bone, 36.7% with lung, 20% with liver, and 10% with brain. Pts received a median number of 8 cycles of ERI (mean dose 1.2 ± 0.19 mg/sqm), 8 cycles of both P and T. Total number of 27 Pts needed to reduce dose of ERI because of adverse events (AEs) especially grade 3 neutropenia. The ORR (CR+PR) was 34.8% (95% CI 16.4-57.3, n=23) with median PFS of 42.6 weeks (95% CI 20.3-51.9, n=30). Clinical benefit rate (CR+PR+≥6 month SD) was 60.9% (95% CI 16.4-57.3%). T-DM1 pretreated affected poor outcome than the other factors (p=0.0011). The most common grade 3/4 AEs were neutropenia in 20 Pts (66.7%) without febrile neutropenia. Grade 1/2 AEs were fatigue in 24 Pts (80%), anorexia in 23 Pts (76.7%), anemia in 22 Pts (73.3%), diarrhea in 20 Pts (66.7%), peripheral neuropathy in 16 Pts (53.3%), and hand-foot syndrome in 12 Pts (43.3%). Baseline LVEF was 67%. One Pt had asymptomatic LVEF decrease (below an absolute value of 55%). Otherwise, there was no overall decrease in mean LVEF from baseline. Nine points (pre-dose, end of infusion, 0.5, 1, 2, 4, 24, 72, and 168 h after ERI) of PK analyses were evaluated in 6 Pts, and 3 point (pre-dose, end of infusion, and 168 h after ERI) in 10 Pts. PK parameters of ERI were as follows; Maximum plasma concentration (Cmax) was 375.96 (257.6-531.8) ng/ml, terminal half-life was 36.807 (31.90-40.80) h, total clearance was 1.945 (1.15-3.15) L/h/m2. Cmax of ERI was not correlated with neutrophil count (R2=0.2338, n=16). Conclusions: The combination of ERI plus P and T was well tolerated; no new safety signals ware observed. PK parameter of ERI were as same as previous reports when combined with both P and T. ERI might be a one of strategy in combination with P plus T for TAX pretreated HER2 positive ABC.
Citation Format: Araki K, Fukada I, Kobayashi K, Takahashi S, Ito Y. Eribulin should be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2 positive advance breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-11.
Collapse
Affiliation(s)
- K Araki
- Breast Medical Oncology, The Cancer Institute Hospital Ariake, the Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
| | - I Fukada
- Breast Medical Oncology, The Cancer Institute Hospital Ariake, the Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
| | - K Kobayashi
- Breast Medical Oncology, The Cancer Institute Hospital Ariake, the Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
| | - S Takahashi
- Breast Medical Oncology, The Cancer Institute Hospital Ariake, the Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
| | - Y Ito
- Breast Medical Oncology, The Cancer Institute Hospital Ariake, the Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
| |
Collapse
|
35
|
Miyazaki R, Kawashima M, Araki K, Higashi M, Hoka S. [Retrospective Evaluation of Hypoxia and Silent Regurgitation during Laparoscopic Sleeve Gastrectomy]. Masui 2017; 66:118-121. [PMID: 30380268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
BACKGROUND The proportion of obese people is gradually increasing. In recent years, laparoscopic sleeve gastrectomy has been performed as a weight loss surgery. We reported the extent of respiratory complications and the keys of anesthetic management in this procedure. METHODS Forty consecutive morbidly obese patients received laparoscopic sleeve gastrectomy. A sample for arterial blood gas analysis was taken after intubation and at the end of the operation. Moreover, to examine the risk of silent aspiration, 16 patients were subjected to measuring the gastric juice volume and pH of the pharynx. RESULTS Oxygenation index (P/F ratio) after intuba- tion was markedly reduced, but there was no correla- tion with the BMI On the other hand, P/F ratio at the end of surgery improved in patients with low BMI Hypercapnia was rare after extubation, but respiratory rate was increased in the patients with high BMI Gas- tric secretion after induction was increased, but there was no overt sign of silent regurgitation of gastric juice. CONCLUSIONS Oxygenation was extremely deterio- rated immediately after intubation in the morbidly obese patients. There is a need for aggressive respira- tory management because intraoperative oxygenation was not improved in the patients with high BMI.
Collapse
|
36
|
Kubota A, Sakuraba K, Ishizuka T, Araki K, Nakaniida A, Suzuki Y. The effect of a stimulus on pelvic floor muscle during voluntary contraction using a facilitating device. J Sci Med Sport 2017. [DOI: 10.1016/j.jsams.2017.01.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Doki T, Yamashita S, Zhang Z, Zhang X, Tawara N, Maeda Y, Hino H, Uyama E, Araki K, Ando Y. Mitochondrial dysfunction in the pathogenesis of oculopharyngeal muscular dystrophy. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Saravia L, Anandhakumar S, Parussulo A, Matias T, Caldeira da Silva C, Kowaltowski A, Araki K, Bertotti M. Development of a tetraphenylporphyrin cobalt (II) modified glassy carbon electrode to monitor oxygen consumption in biological samples. J Electroanal Chem (Lausanne) 2016. [DOI: 10.1016/j.jelechem.2016.05.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Hatano T, Tsukahara T, Araki K, Kawakami O, Murakami N. Stenting for Stenoses of the Proximal Vertebral Artery. Interv Neuroradiol 2016; 5:301-6. [DOI: 10.1177/159101999900500406] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/1999] [Accepted: 10/25/1999] [Indexed: 11/16/2022] Open
Abstract
We report our initial experience of stenting for symptomatic stenoses of the proximal vertebral artery. A total of 25 lesions affecting the proximal vertebral artery were treated by PTA with stent in 23 patients. The lesions involved the vertebral artery ostium in 20 lesions and the nonostial V1 portion in five lesions. The mean stenosis rate of those lesions was 81% pre-stenting and was reduced to 4% post-stenting. There were two transient neurological complications: hemiparesis in one patient and visual acuity disturbance in another. Angiographic follow-up studies more than three months after treatment demonstrated restenosis in three patients. One of these patients was symptomatic. These restenoses were successfully treated by PTA. Our initial results demonstrated that stenting is a feasible and safe method of treating stenosis of the proximal vertebral artery.
Collapse
Affiliation(s)
- T. Hatano
- Department of Neurosurgery and Clinical Research Unit, Kyoto National Hospital; Kyoto, Japan
| | - T. Tsukahara
- Department of Neurosurgery and Clinical Research Unit, Kyoto National Hospital; Kyoto, Japan
| | - K. Araki
- Department of Neurosurgery and Clinical Research Unit, Kyoto National Hospital; Kyoto, Japan
| | - O. Kawakami
- Department of Neurosurgery and Clinical Research Unit, Kyoto National Hospital; Kyoto, Japan
| | - N. Murakami
- Department of Neurosurgery and Clinical Research Unit, Kyoto National Hospital; Kyoto, Japan
| |
Collapse
|
40
|
Fukada I, Araki K, Kobayashi K, Gomi N, Horii R, Akiyama F, Takahashi S, Iiwase T, Ohno S, Ito Y. Abstract P4-02-13: The pattern of tumor shrinkage is associated with prognosis in low grade luminal early breast cancer during neoadjuvant chemotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-02-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: In neoadjuvant chemotherapy (NAC) for early breast cancer, the pathological response rate in estrogen receptor (ER)-positive tumors has been low in comparison with those of ER-negative tumors. Therefore, surrogate makers other than the pCR rate are needed during NAC for luminal breast cancer. Using MRI, we analyzed the patterns of tumor shrinkage after NAC as a surrogate prognostic factor in low grade luminal breast cancer. METHODS: Of 854 patients who had received NAC in a single institute from Jan. 2000 to Dec. 2009, 183 patients with low grade luminal breast cancer were retrospectively evaluated for this study. They were defined as ER and/or PgR positive in more than 10% of cancer cells and HER2 negative (IHC 0, 1+ or FISH <2.0) with nuclear grade 1 and 2. RESULTS: The median observation period was 67.9 months following surgery, and recurrence was observed in 31 patients (16.9%). The median age was 49 (22-76) years. One hundred eighty patients received anthracycline-containing chemotherapy, and 158 received taxane. There were 16 deaths (8.7%) related to breast cancer. We categorized the patterns of tumor shrinkage by MRI into 6 types: concentric shrinkage (CS), diffuse decrease (DD), reduction to small foci (RSF), decrease of intensity only (DIO), no change (NC), and enlargement (EL). According to our categorization, CS occurred in 97 (53.0%), RSF in 7 (3.8%), DD in 62 (33.9%), DIO in 7 (3.8%), NC in 5 (2.7%), and EL in 5 (2.7%). As expected, there were statistically significant differences in both the median DFS and OS in each pattern of tumor shrinkage (p <0.001 and p=0.001, respectively); in particular, the CS pattern had excellent prognosis. Multivariate analysis demonstrated that concentric shrinkage was the only significant good prognostic factor for OS (p=0.015). CONCLUSIONS: Tumor shrinkage patterns as revealed by MRI could be important surrogate prognostic factors for NAC in early low grade luminal breast cancer.
Citation Format: Fukada I, Araki K, Kobayashi K, Gomi N, Horii R, Akiyama F, Takahashi S, Iiwase T, Ohno S, Ito Y. The pattern of tumor shrinkage is associated with prognosis in low grade luminal early breast cancer during neoadjuvant chemotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-02-13.
Collapse
Affiliation(s)
- I Fukada
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - K Araki
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - K Kobayashi
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - N Gomi
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - R Horii
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - F Akiyama
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - S Takahashi
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - T Iiwase
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - S Ohno
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - Y Ito
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| |
Collapse
|
41
|
Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Abstract P3-14-10: Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-14-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Taselisib (GDC-0032) is an orally bioavailable, potent and selective phosphoinositide 3-kinase (PI3K) inhibitor. Preclinical data showed that taselisib had increased antitumor activity against PIK3CA (gene encoding the PI3Kα isoform) mutant tumors. This study aimed to investigate the safety, tolerability and pharmacokinetics (PK) of taselisib as monotherapy and in combination with fulvestrant in Japanese patients (pts).
Materials and methods:
A 3+3 design was used. In Phase Ia, pts with advanced solid tumors received taselisib tablet monotherapy (2, 4 or 6 mg once daily [QD]), and safety and PK were evaluated. In Phase Ib, pts with hormone receptor-positive locally advanced or metastatic breast cancer received taselisib (2 or 4 mg QD) in combination with fulvestrant (500 mg at a time), and safety and PK were evaluated. Maximal administered doses of 6 mg QD as a single agent and 4 mg QD in combination with fulvestrant were based upon prior clinical trial experience with taselisib (Juric D. et al. AACR 2013, Abstract LB-64; Juric D. et al. SABCS 2013, Abstract PD1-3).
Results:
As of 15 Mar 2015, 9 pts (PIK3CA mutant: 2 pts) were enrolled in Phase Ia and 3 pts in Phase Ib. Phase Ia dose-escalation study has been completed and Phase Ib is ongoing.
In Phase Ia, no dose-limiting toxicity (DLT) was observed at any dose level tested (maximum administered dose of 6 mg QD). Common (≥3 pts) adverse reactions (ARs) were stomatitis (4 pts), rash (3 pts) and diarrhea (3 pts); the only Grade ≥3 AR was neutropenia (1 pt). Partial response was observed in 1 pt who received taselisib 4 mg and had a PIK3CA mutant breast tumor. Stable disease was observed in 4 pts. Cmax and AUC indicated a dose-proportional PK profile of taselisib within the dose range tested. Moreover, taselisib PK in Japanese pts was consistent with the PK reported from North American and European pts (Juric D. et al. AACR 2013, Abstract LB-64).
In Phase Ib, 3 pts received taselisib 2 mg in combination with fulvestrant and no DLT was observed. Preliminary ARs were similar to those with monotherapy and no Grade ≥3 AR was reported. Confirmation of tolerability of taselisib 4 mg in combination with fulvestrant is under evaluation.
Conclusion:
Taselisib monotherapy was well tolerated in Japanese pts up to a dose of 6 mg, which is the recommended dose in non-Japanese pts. Promising preliminary activity of monotherapy was observed in advanced solid tumors, especially in a pt with PIK3CA mutant tumor. The combination of taselisib 2 mg with fulvestrant is well tolerated. Investigation of tolerability of taselisib 4 mg in combination with fulvestrant is ongoing. Final results of this study will be presented here at the Symposium this year.
Citation Format: Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-10.
Collapse
Affiliation(s)
- T Kobayashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Nakano
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - J Tomomatsu
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - E Nara
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - Y Ito
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Kobayashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - I Fukada
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Araki
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - A Shimomura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - T Shimoi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Kodaira
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Yunokawa
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Yonemori
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - C Shimizu
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Nakamura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - N Kotani
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Inatani
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Tamura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - S Takahashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| |
Collapse
|
42
|
Gonçalves JM, Guimarães RR, Nunes CV, Duarte A, Brandão BBNS, Toma HE, Araki K. Electrode materials based on α-NiCo(OH)2 and rGO for high performance energy storage devices. RSC Adv 2016. [DOI: 10.1039/c6ra20317e] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Described herein is a composite material based on rGO and α-NiCo(OH)2 nanoparticles combining very fast charge/discharge processes with the high energy density of batteries, suitable for application in high performance energy storage devices.
Collapse
Affiliation(s)
- J. M. Gonçalves
- Department of Fundamental Chemistry
- University of Sao Paulo
- São Paulo
- Brazil
| | - R. R. Guimarães
- Department of Fundamental Chemistry
- University of Sao Paulo
- São Paulo
- Brazil
| | - C. V. Nunes
- Department of Fundamental Chemistry
- University of Sao Paulo
- São Paulo
- Brazil
| | - A. Duarte
- Department of Fundamental Chemistry
- University of Sao Paulo
- São Paulo
- Brazil
| | | | - H. E. Toma
- Department of Fundamental Chemistry
- University of Sao Paulo
- São Paulo
- Brazil
| | - K. Araki
- Department of Fundamental Chemistry
- University of Sao Paulo
- São Paulo
- Brazil
| |
Collapse
|
43
|
Abstract
As CBCT is widely used in dental and maxillofacial imaging, it is important for users as well as referring practitioners to understand the basic concepts of this imaging modality. This review covers the technical aspects of each part of the CBCT imaging chain. First, an overview is given of the hardware of a CBCT device. The principles of cone beam image acquisition and image reconstruction are described. Optimization of imaging protocols in CBCT is briefly discussed. Finally, basic and advanced visualization methods are illustrated. Certain topics in these review are applicable to all types of radiographic imaging (e.g. the principle and properties of an X-ray tube), others are specific for dental CBCT imaging (e.g. advanced visualization techniques).
Collapse
Affiliation(s)
- R Pauwels
- 1 Department of Radiology, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand
| | | | | | | |
Collapse
|
44
|
Tanaka N, Araki K, Mizokami D, Miyagawa Y, Yamashita T, Tomifuji M, Ueda Y, Inoue M, Matsushita K, Nomura F, Shimada H, Shiotani A. Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer. Gene Ther 2015; 22:297-304. [PMID: 25588744 DOI: 10.1038/gt.2014.123] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Revised: 10/03/2014] [Accepted: 11/20/2014] [Indexed: 01/25/2023]
Abstract
Far-upstream element-binding protein-interacting repressor (FIR) is a transcription factor that inhibits c-Myc expression and has been shown to have antitumor effects in some malignancies. Here, we evaluated the antitumor effects of FIR using fusion gene-deleted Sendai virus (SeV/ΔF) as a nontransmissible vector against head and neck squamous cell carcinoma (HNSCC). Using in vitro and in vivo xenograft mouse models, we observed efficient expression of green fluorescent protein (GFP) following transduction with the SeV/ΔF vector encoding GFP (GFP-SeV/ΔF) into HNSCC cells. In vitro and in vivo studies revealed that administration of the FIR-encoded SeV/ΔF (FIR-SeV/ΔF) vector exerted significant antitumor effects, suppressed c-Myc expression and induced apoptosis in HNSCC. Additionally, the antitumor effects of FIR or the expression of GFP following administration of the FIR- or GFP-SeV/ΔF vector, respectively, were dependent on the multiplicity of infection or titer. Furthermore, the SeV/ΔF vector itself had no cytotoxic effects. Therefore, the SeV/ΔF vector may be safe and useful for the treatment of HNSCC, allowing for high-titer SeV/ΔF vector administration for anticancer gene therapy. In addition, SeV/ΔF vector-mediated FIR gene therapy demonstrated effective tumor suppression in HNSCC, suggesting that this therapy may have the potential for clinical use as a novel strategy for HNSCC treatment.
Collapse
Affiliation(s)
- N Tanaka
- Department of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan
| | - K Araki
- Department of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan
| | - D Mizokami
- Department of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan
| | - Y Miyagawa
- Department of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan
| | - T Yamashita
- Department of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan
| | - M Tomifuji
- Department of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan
| | - Y Ueda
- Department of Gene Medicine, DNAVEC Corporation, Ibaraki, Japan
| | - M Inoue
- Department of Gene Medicine, DNAVEC Corporation, Ibaraki, Japan
| | - K Matsushita
- Department of Molecular Diagnosis and Division of Clinical Genetics and Proteomics, Chiba University Graduate School of Medicine, Chiba, Japan
| | - F Nomura
- Department of Molecular Diagnosis and Division of Clinical Genetics and Proteomics, Chiba University Graduate School of Medicine, Chiba, Japan
| | - H Shimada
- Department of Surgery, Toho University School of Medicine, Tokyo, Japan
| | - A Shiotani
- Department of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan
| |
Collapse
|
45
|
Abstract
OBJECTIVES The aim of this study was to analyse the position and relationship of juxta-apical radiolucency (JAR) to the mandibular canal and buccal and/or lingual cortical plates using cone beam CT (CBCT). METHODS A retrospective study was carried out to analyse the JAR on CBCT for 27 patients. These findings were compared with 27 age- and sex-matched patients without the presence of JAR, which acted as the control group. The CBCT images were analysed according to a checklist, to evaluate the position of the JAR and its relationship to the mandibular canal. Then, any thinning or perforation of either the buccal or lingual cortical plate due to JAR was noted, and a classification to quantify the thinning of cortical plates was proposed. The findings in the two groups were analysed using a paired comparison by McNemar test. RESULTS A statistical increased thinning of cortical plates was seen in the JAR group compared with the control group, and most of the cases were in the J3 group. None of the patients in either the JAR or the control group showed perforation of the buccal and/or lingual cortical plate on CBCT images. CONCLUSIONS A classification to quantify the thinning of cortical plates was proposed, which may be used for objective evaluation of the thinning of the cortical plates in future studies. The present study gives an insight into the relationship of the juxta-apical area with the mandibular canal and cortical plates in the mandible using CBCT.
Collapse
Affiliation(s)
- R Kapila
- 1 Division of Radiology, Department of Oral Diagnostic Sciences, Showa University School of Dentistry, Tokyo, Japan
| | | | | | | | | |
Collapse
|
46
|
Abstract
The higher-order structures of the zinc chlorophyll coordination polymers were controlled by the regiochemistry of the coordination sites.
Collapse
Affiliation(s)
- Y. Shinozaki
- College of Science and Technology
- Nihon University
- Chiyoda-ku, Japan
| | - I. Yoshikawa
- Institute of Industrial Science
- University of Tokyo
- Meguro-ku, Japan
| | - K. Araki
- Institute of Industrial Science
- University of Tokyo
- Meguro-ku, Japan
| | - K. Sugawa
- College of Science and Technology
- Nihon University
- Chiyoda-ku, Japan
| | - J. Otsuki
- College of Science and Technology
- Nihon University
- Chiyoda-ku, Japan
| |
Collapse
|
47
|
Araki K, Fukada I, Takahashi S, Ito Y. Abstract P6-06-45: Predictive significance of the mucocutaneous toxicities, but not dose intensity of capecitabine for the treatment of lapatinib plus capecitabine in patients with HER2 positive metastatic breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There are no definitive predictive markers, except HER2 overexpression, for anti-HER2 therapeutic sensitivity of patients (Pts) with HER2-positive breast cancer. The aim of this study was to evaluate clinical predictive factors for lapatinib plus capecitabine (LAPCAP) in Pts with HER2 positive metastatic breast cancer (HER2MBC).
Methods: This retrospective observational study was used data from our single institutional medical record system from June 2009 to March 2013. Evaluation of female Pts with HER2MBC who were treated with LAPCAP (LAP at 1250 mg/day continuously plus CAP at 2000 mg/m2 on days 1 through 14 of a 21-day cycle) included baseline clinical characteristics, dose modifications of LAPCAP, clinical efficacy, and incidence of adverse events (AEs). Dose-intensity was compared with reference standard regimens. The Kaplan Meier method was used to estimate time to progression free survival (PFS).
Results: A total 76 Pts were included in this analysis. At a median follow-up of 20 months, median age was 56 years (range, 36 to 75) and 41 of 76 Pts had received prior (neo- or) adjuvant chemotherapy including 18 trastuzumab (Tmab) containing regimen. Visceral metastases (Mets) were identified in 49, bone Mets in 37, lymph nodes Mets in 36, brain Mets in 17, and chest wall Mets in 16. The median number of prior chemotherapy or hormonal therapy for MBC before LAPCAP was 2 (range, 0 to 13), and 66 of 76 Pts had previously received Tmab containing regimen with taxanes for 40 Pts, vinorelbine for 36, CAP for 29, and hormonal therapies for 15. In LAPCAP, the overall response rate was 21% including 2 CRs and 14 PRs, and the clinical-benefit rates which had more than 6-month SD was 60%. During initial 12 months observation, 93% of Pts had any AEs. The most common AEs were hand-foot syndrome (HFS) in 55 Pts. Those Pts who had HFS had better PFS than those who did not have (p = 0. 23×10−4). Since HFS was one of the well-known AEs associated with CAP, we sought whether CAP dose influenced PFS or not. However, we did not find any relationship between cumulative or relative dose intensity of CAP and PFS in Pts who treated with LAPCAP. Because several studies with EGFR-targeted agents showed a positive correlation between cutaneous toxicities and outcomes, we sought whether the incidence of any AEs other than HFS influenced PFS in 76 Pts. HFS, and diarrhea, as well as skin rash were statistically significant favorable factors (p = 0. 23×10−4, 0. 60×10−2, and 0. 28×10−1) in Log rank analysis. Furthermore, median PFS of Pts who had all 3 AEs (n = 21) were 377 days, while 84 days (n = 7) who had not (p = 0.58×10−8). We did not find any other clinical predictive factors except these 3 AEs. Furthermore, we compared 20 Pts with longer PFS who had more than 12-month to 26 Pts with shorter PFS that had less than 6-month. Longer PFS had more statistically significant incidence of diarrhea (p = 0. 49×10−2), HFS (p = 0. 49×10−2), and skin rash (p = 0.36×10−1) than shorter one.
Conclusions: In LAPCAP, dose of CAP did not influence PFS, but EGFR inhibitor related toxicities might be alternative predicative markers for LAPCAP in HER2MBC.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-45.
Collapse
Affiliation(s)
- K Araki
- Cancer Institute Hospital - The Cancer Institute of the Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, Japan
| | - I Fukada
- Cancer Institute Hospital - The Cancer Institute of the Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, Japan
| | - S Takahashi
- Cancer Institute Hospital - The Cancer Institute of the Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, Japan
| | - Y Ito
- Cancer Institute Hospital - The Cancer Institute of the Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, Japan
| |
Collapse
|
48
|
Araki K, Fukada I, Kobayashi K, Takahashi S, Ito Y. Toxicities Can Be a Surrogate Predictive Marker for Lapatinib Efficacy in Patients with HER2 Positive Breast Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Fukada I, Kobayashi K, Kobayashi T, Araki K, Takahashi S, Ito Y. Therapeutic Effect of Taxane for the Metastatic and Recurrent Breast Cancer in Intrinsic Subtypes. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Abstract
OBJECTIVES In the 2011 project "Safety and efficacy of a new and emerging dental X-ray modality (SEDENTEXCT)", it was suggested that dose index (DI) and dose-area product (DAP) could be easily measured and used as diagnostic reference levels (DRLs), which would help in the management of radiation doses to patients in optimum exposure settings. Such indices could be directly related to effective dose. The purposes of this study, therefore, were to measure and calculate the DI and DAP in cone beam CT (CBCT) machines and to evaluate the correlation between the two. METHODS Dose measurements were performed on three-dimensional cone beam CT (3D-CBCT) machines [3D Accuitomo (J. Morita Mfg. Corp., Kyoto, Japan), Veraviewepocs (J. Morita Mfg. Corp.) and CS9300 (Carestream, New York, NY)] by exposing a cylindrical poly-methyl methacrylate (PMMA) phantom using a CT ionization chamber. These dose measurements were used for the calculation of Dose Indices 1 and 2, according to the methodology suggested by SEDENTEXCT. The DAP was measured using a DAP meter that was attached to the detector to cover the entire irradiated area. RESULTS The DI1 ranged from 53.6 mR to 216.6 mR, the DI2 ranged from 77.1 mR to 325.0 mR and the DAP ranged from 101.1 mGy cm(2) to 457.9 mGy cm(2), depending on the machines and exposure settings. Index 2 had a better correlation with the DAP than Index 1. CONCLUSIONS The DIs and DAP proposed by SEDENTEXCT may be useful for establishing DRLs for dental CBCT machines; however, further studies are necessary to determine which of these indices provide accurate dose estimates proportionally relating to the effective dose.
Collapse
Affiliation(s)
- K Araki
- Department of Oral Diagnostic Sciences, Showa University School of Dentistry, Ota-ku, Tokyo, Japan.
| | | | | | | |
Collapse
|